AbCellera BiologicsABCL
About: AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Employees: 586
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
43% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 35
3.5% less ownership
Funds ownership: 39.03% [Q2] → 35.53% (-3.5%) [Q3]
5% less funds holding
Funds holding: 146 [Q2] → 138 (-8) [Q3]
20% less capital invested
Capital invested by funds: $339M [Q2] → $272M (-$67.3M) [Q3]
29% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 28
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
51% less call options, than puts
Call options by funds: $407K | Put options by funds: $837K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Stifel Stephen Willey 50% 1-year accuracy 8 / 16 met price target | 296%upside $12 | Buy Reiterated | 5 Nov 2024 |
Financial journalist opinion
